ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2022 - 2026)

ARS Pharmaceuticals has reported Other Working Capital Changes for 5 years, with the latest figure at -$61000.0 in Q1 2026.

• Quarterly Other Working Capital Changes rose 70.95% year-over-year to -$61000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201000.0 (down 110.7% YoY) and the FY2025 annual result came in at -$350000.0, down 116.75% from the prior year.
• Other Working Capital Changes eased to -$61000.0 in Q1 2026 per SPRY's latest filing, from -$55000.0 in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $7.3 million in Q4 2024 and troughed at -$4.1 million in Q2 2025.
• A 5-year average of $510588.2 and a median of -$92000.0 in 2022 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 97.84% in 2023, down 371.64% in 2023.
• Over 5 years, Other Working Capital Changes stood at -$189000.0 in 2022, then surged by 94.71% to -$10000.0 in 2023, then soared by 20990.0% to $2.1 million in 2024, then sank by 102.63% to -$55000.0 in 2025, then slipped by 10.91% to -$61000.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$61000.0, -$55000.0, and -$55000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.